Castle Biosciences (CSTL) recently lifted its 2026 revenue guidance to a range of US$385 million to US$395 million, citing stronger TissueCypher test volumes and some pricing improvement as key drivers.
Recent trading reflects that shift in expectations. The share price is up 12.82% over the past 90 days and 5.73% over the last month, yet it is still down 12.32% year to date. Meanwhile, the 3 year total shareholder return of 72.05% points to a much stronger longer term payoff profile than the 5 year total shareholder return of a 28.86% loss.
Spot under-the-radar peers that may benefit from similar guidance shifts by scanning our hand picked list of 19 high quality undiscovered gems in the healthcare and diagnostics space.After the guidance bump and sharp 90 day rebound, Castle Biosciences now sits in awkward territory for investors. Is today’s price already baking in the good news, or does patience offer a cleaner entry point?
On the analyst consensus Narrative on Simply Wall St, Castle Biosciences screens as undervalued, with a fair value of $45.22 against the last close at $33.79, which frames the recent guidance hike against a still discounted price.
Castle Biosciences is expanding its test menu into underpenetrated indications such as Barrett’s esophagus and atopic dermatitis, with TissueCypher volumes rising 63% to 14,988 reports in Q2 2026 and AdvanceAD-Tx orders progressing from about 650 in Q1 2026 to more than 1,000 in Q2 2026. This points to broader exposure to new patient groups and potential support for future revenue growth.
See why 4 investors see Castle Biosciences as 25% undervalued.
Result: Fair Value of $45.22 (UNDERVALUED)
Still, the narrative around Castle Biosciences can break if Medicare reimbursement for DecisionDx SCC tightens further or if lower margin assays keep pressing gross margin guidance toward the low 70% range.
Find out about the key risks to this Castle Biosciences narrative.
Sentiment on Castle Biosciences is mixed, with clear concerns balanced by genuine upside potential. Move quickly and test the data for yourself by weighing 3 key rewards and 1 important warning sign.
If you stop with Castle Biosciences, you may miss other setups with similar upside and different risk profiles hiding elsewhere in the market.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com